PacingCure wins the Venture Challenge 2020
December 7, 2020Amsterdam UMC spin-off PacingCure is the winner of the Venture Challenge at the online edition of the Dutch Life Science Conference on the 26th of November. PacingCure develops precision gene therapies for common cardiac arrhythmias and cardiomyopathies, aiming to restore the natural pacing of the heart. The company is founded on combined research from the departments of Cardiology and Medical Biology of the AMC.
The PacingCure team, consisting of Geert Boink, Hanno Tan and Osne Kirzner, participated in the summer edition of the Venture Challenge. In this 10-week bootcamp program, life science start-ups work to sharpen and validate their business idea. During the program, the participating start-ups produce a venture plan and pitch their business in front of an expert jury. This year, the jury consisting of Carine van den Brink, Eline Vrijland, Andre van de Sande, Kim Lucassen and Geert-Jan Mulder, agreed that “PacingCure is addressing a high unmet medical need that they can target with their gene-therapy. They have identified a clear first orphan indication to prove their technique. Moreover, they are a very experienced team of clinicians.”
PacingCure is awarded €25.000,- in price money that they will invest in the further growth of their company. The vision of the company is to become a world leader in cardiac gene therapy.
PacingCure is developing therapies that offer superior treatment over established implantable and medicinal therapies to patients suffering from severe morbidity and mortality, and a cure for patients who are currently untreatable. Their in-vivo validated gene therapies are injected directly into a small region of the heart using a simple, minimal-invasive procedure.
More news
Tackling learning difficulties in Academic Workplace
The Academic Workplace Rudolf Berlin Center (AW RBC) aims to make a meaningful contribution by supporting young people with learning disabilities through enhanced education and care.
News
Contribute to Amsterdam’s Future: test your innovation at SAIL and the Amsterdam Marathon
Are you looking for a testing ground for your innovation? SAIL and the Amsterdam Marathon present an excellent opportunity to test your ideas. These major events attract millions of visitors and come with sustainability, accessibility, and logistical challenges that need fresh solutions. The In Residence Events program allows you to test your innovation during these […]
News
VU researchers develop research equipment to identify contaminants in water
Water, comprising over 70% of our planet, is the source of all life. The presence of emerging contaminants in our water, including pharmaceuticals, pose serious health and environmental risks, such as DNA damage, reproductive issues, and cancer. New equipment to detect these contaminants developed by VU researchers has been sold to other research groups all over the world. Now the researchers are taking the next step, together with IXA, to expand sales to water companies worldwide as well as other applications such as food and drug discovery research.
News